Click on a field for details on how to access that data via Web API, Excel, or CSV File Download.
| Open Price | |
| High Price | |
| Low Price | |
| Close Price | |
| Change | |
| Percent Change | |
| Volume |
| Avg Daily Volume | 273,276 |
| 52 Week High | $42.29 |
| 52 Week Low | $23.23 |
| Target Price | $42.00 |
| Ticker | COLL:UW |
| Composite Ticker | COLL:US |
| Security Name | Collegium Pharmaceutical Inc |
| Type | Ordinary Shares |
| Class | COLL |
| Currency | USD |
| Round Lot Size | 100 |
| Primary | Yes |
| Delisted | No |
| ETF | No |
| Market Category | Common Stock |
| Market Sector | N/A |
| Exchange Symbol | ^USCOMP |
| Exchange Name | US COMPOSITE |
| Exchange City | N/A |
| Exchange Country | UNITED STATES OF AMERICA |
| Exchange Website | N/A |
| FIGI | BBG008G2NTG4 |
| Composite FIGI | BBG000N7LPW4 |
| Share Class FIGI | BBG001T535S9 |
| FIGI Unique ID | EQ0000000008629870 |
| Dividend | N/A |
| Dividend Rate | N/A |
| Trailing Dividend Yield | 0.00% |
| 5-year Average Dividend Yield | 0.00% |
| Dividend Ex Date | N/A |
| Beta | 0.4055 |
| 1-year beta | 0.1734 |
| 3-year beta | 0.4055 |
| 5-year beta | 0.5668 |
| 7-year beta | 0.8041 |
| 10-year beta | 0.913 |
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
